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Proton pump inhibitors (PPIs) have been established as the new "gold standard"
for traditional acid-inhibitory treatment of the so called "peptic" diseases. Due
to the high antisecretory and ulcer-healing potency of omeprazole, no major
improvements of the efficacy in ulcer healing and pain relief can be expected.
Pantoprazole, as a further development in PPIs, is characterized by improved
pharmacokinetic behavior as well as by higher tissue selectivity and binding
specificity and by a very low potential to interact with the cytochrome P40
enzyme system. These characteristics may provide the basis for a low potentlal
for side effects and for a more favorable interaction profile, although the clini-
cal relevance of these potential advantages remains to be proven. Reflux
esophagitis will also remain a domain for the traditional use of PPIs in the
future. However, in the treatment of gastroduodenal ulcers, the acid inhibitory
potential ofPPIs will be used mainly to facilitate the eradication ofH. pylori.
INTRODUCTION
Since Schwarz's dictum "no acid - no ulcer" was coined in 1910 [1], treatment of
reflux esophagitis and gastro-duodenal ulcers has been awaiting modalities providing
effective control of gastric acid secretion. It was not until the late 1960s that antacids
became available. These, however, just partially neutralized gastric acid that already had
been secreted. Thus, symptom control and healing rates were unsatisfactory. These disap-
pointing results, together with the inconvenience offrequent drug intake, resulted in poor
patient compliance.
It was only logical that antacids were rapidly replaced by antagonists acting at the
parietal cell histamine H2 receptors. For the first time these drugs provided effective inhi-
bition of production and release of gastric acid via a pharmacologically well-defined
mechanism and became the gold standard of acid inhibitory therapy in the late 1970s.
However, H2 receptor antagonists (H2RAs)b do not block parietal cell stimulation by ago-
nists otherthan histamine, e.g., vagal acetylcholine interacting withparietal cellM3 recep-
tors. Moreover, H2RAs are far more effective in inhibiting nocturnal than day-time acid
secretion. Furthermore, theefficacy ofthesedrugs declines afterseveral days oftreatment.
These shortcomings were overcome when proton pump inhibitors (PPIs) became
available for clinical use in the late 1980's. Their superior antisecretory potency provided
an excellent basis toreplace H2RAs as the gold standard in the therapy ofacid-related dis-
eases. In the following, clinical results of treatment with PPIs, which have established
these compounds as the drugs of choice, will be reviewed. Thereafter, potential advan-
tages of further developments in PPIs will be evaluated. Finally, rationales will be dis-
cussed for the use of PPIs in a new indication, eradication of the bacterium Helicobacter
pylori from the gastric mucosa.
aTo whomallcorrespondence shouldbeaddressed: Prof. Dr. WolfgangSchepp, SecondDepartment
of Internal Medicine, Technical University of Munich, Ismaninger Strasse 22, 81675-Munich,
Germany. Tel: 49-89-4140-4074 (2483); Fax: 49-89-4140-4932.
bAbbreviations: H2RA, H2 receptor antagonists; PPI, proton pump inhibitor; NSAID, non-steroidal
anti-inflammatory drug.
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THEN: CLINICAL RESULTS
Reflux esophagitis
PPIs are superior to H2RAs in healing acute erosive reflux esophagitis (Savary and
Miller grades II-IV). In numerous studies the healing rates after four, eight and 12 weeks
ofdaily treatment with PPIs were 60, 85 and 95 percent; the corresponding healing rates
with standard doses ofH2RAs were 35, 50, and 65 percent [2-6], the majority ofpatients
being classified as grades II (-III) according to Savary and Miller. PPIs have proven to be
especially valuable in the treatment of reflux esophagitis refractory to treatment with
H2RAs, since within 8 to 12 weeks ofdaily treatment with 40 mg omeprazolehealing was
achieved in almost all patients [7]. Even more important to the patient, pain relief occurs
faster upon treatment with PPIs than with H2RAs. Complete freedom from pain was
reported by 65 percent, 85 percent, and 95 percent ofpatients treated with omeprazole for
four, eight and 12 weeks, while the corresponding data ofpatients on H2RAs were 30, 50
and 60 percent [2-6]. With the PPIs that were developedlater, lansoprazole and pantopra-
zole, similar results have been obtained as with omeprazole with respect to heialing and
symptom relief in the acute treatment of reflux esophagitis [8-10]. However, it must be
kept in mind that with the laterdeveloped drugs the number ofpatients studied is consid-
erably lower than with omeprazole, especially when the focus is on severe esophagitis.
Placebo-controlled studies have shown that, when treatment is stopped after healing
of acute reflux esophagitis, therelapse rate is about 65 percent per year in unselected, pri-
mary-care populations [11-13] and 82 percent per six months in selected, i.e., H2RA-
refractory, patients [14]. Maintenance therapy with H2RAs is not superior to placebo [11,
12, 15] and significantly less effective than prophylaxis with PPIs [11, 16-19]. In a pri-
mary care population, symptomatic remission was maintained over 12 months in 72 per-
cent, 62 percent and 45 percent ofpatients on 20 mg omeprazole daily, 10 mg omeprazole
daily and 150 mg ranitidine twice daily, respectively [20]. The difference between the 10
and 20 mg omeprazole dose narrowly missed statistical significance (p = .06) when symp-
tomatic relapses were evaluated [20]; however, the higheromeprazole dose appeared to be
significantly (p = .003) [20] or atleastnumerically [21] more effectivein preventing endo-
scopic relapses, the remission rates after 12 months being 77 percent, 58 percent and 46
percent, respectively, for 20 mg omeprazole daily, 10 mg omeprazole daily and 150 mg
ranitidine twice daily [20]. As expected, relapses are more frequent in selected, i.e.,
H2RA-refractory, patients apparently requiring a more intense antisecretory treatment. In
thesepatientsendoscopic remission rates of67 percent [22] and 10-25 percent [11, 12, 15-
18] were observed after 12 months on prophylactic treatment with standard doses of
omeprazole or ranitidine, respectively. Based on a long-term observation of selected
patients initially refractory to healing with H2RAs, life-table analysis revealed that after
five years on continuous prophylaxis with omeprazole (20 mg o.d.) 55 percent were still
in remission [23]. The prophylactic effect of PPIs is independent of the grade of reflux
esophagitis prior to the initial treatment, initial healing dose of PPIs, and of smoking
habits [17, 23]. Continuous maintenance treatment is superior to discontinuous approach-
es, e.g., weekend therapy (Friday, Saturday, Sunday) [16, 19, 24-26]. In maintaining
remission, theprokinetic cisapride was moreeffective than ranitidine butsignificantly less
effective thanomeprazole [27]. On the otherhand, the efficacy ofranitidine was improved
by combination with cisapride; however, even this combination was less effective than
omeprazole alone, the prophylactic effect ofwhich was not significantly increased by cis-
apride [27].
Peptic strictures complicating reflux esophagitis (Savary and Miller grade IV) tend to
relapse at a high frequency (about 50 percent within 12 months) [28, 29]. Following
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dilatation, relapse prophylaxis with H2RAs has yielded disappointing results [30, 31]. On
the other hand, omeprazole (20 mg daily) reduced the need for repeat dilatation by more
than 50 percent (0.48 per year) when compared to ranitidine (150 mg twice daily) (1.08
repeat dilatations per year) [32]. Omeprazole was significantly more effective than raniti-
dine in relieving symptoms (freedom from dysphagia (76 vs. 64 percent); acceptance of
normal diet (83 vs. 69 percent); increase in median body weight (1.9 vs. 0.4 kg) [32]. This
study confirmed earlier disappointing results with H2RAs and the superiority of PPIs in
preventing repeat dilatation [33].
Gastric ulcers
PPIs have been established as superior to H2RAs in the treatment ofgastric ulcer. In
three randomized double-blind studies [34, 35, 36], healing rates after four and eight
weeks of treatment were 73 percent and 92 percent with omeprazole 20 mg every morn-
ing, and 62 percent and 86 percent with twice-daily ranitidine according to the per-proto-
col analysis. Likewise, omeprazole was superior to cimetidine [37]. Continuing intake of
NSAIDs resulted in slightly lower four-week healing rates with omeprazole (61 percent)
and ranitidine (53 percent) [34]. Symptom relief was significantly faster in patients on
omeprazole than in those on H2RAs [34-37].
With respect to healing rates and symptom reliefsimilar superiority, over H2RAs has
been observed with pantoprazole (40 mg every morning) and lansoprazole (30 mg every
morning) [38, 39] while these later developed PPIs were equally effective as omeprazole
[40, 41].
Duodenal ulcers
The superiority ofPPIs over H2RAs has also been established in the treatment ofduo-
denal ulcer. According to per-protocol analysis ofdouble-blind randomized trials, healing
rates after two and four weeks oftreatment were 64 percent and 92 percent with omepra-
zole 20 mg every morning. and 48 percent and 80 percent with ranitidine 150 mg twice
daily [42-49] or 300 mg at night [50-57]. Likewise, omeprazole was superior to cimeti-
dine [58-63]. In the identical studies, omeprazole proved to be significantly more effec-
tive than H2RAs in inducing overall symptom reliefas well as daytime and nighttime pain
relief [50-63].
A similar pattern ofsuperiority was observed in trials comparing pantoprazole or lan-
soprazole with H2RAs [64,65]. On the other hand both later developed PPIs were equal-
ly effective as omeprazole [66,67].
In summary, PPIs speed up the healing process of gastric and duodenal ulcers more
effectively than H2RAs. The latter class of drugs is also capable of healing almost all
benign gastric ulcers, however, a significantly longer time is needed to achieve healing
and symptom relief.
Refractory peptic lesions
Esophageal, gastric and duodenal lesions that do not heal on prolonged adminis-
tration orincreased doses ofH2RAs are regarded refractory to treatment by H2RAs. These
lesions require the higher acid inhibitory potency provided by PPI treatment. Omeprazole
[68], pantoprazole [69] andlansoprazole [70] were shown to rapidly heal all H2RA-refrac-
tory peptic lesions within 12 weeks, and most ofthem within four weeks. Thus, nowadays
any peptic lesions should not be regarded refractory unless they do not heal upon PPI
treatment. Such lesions are extremely rare and in most cases attributable to intake of sal-
icylates, rarely to rapid PPI metabolism.
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Gastrinoma (Zollinger-Ellison Syndrome)
Even more than H2RA-refractory lesions, gastrinoma patients represent the ultimate
test of the efficacy of acid-inhibitory therapy. These patients are characterized by exces-
sive gastrin secretion from endocrine tumors maintaining a continuous maximal stimula-
tion of acid production, which results in severe reflux esophagitis and multiple and fre-
quently recurrent ulcers of the upper gastrointestinal tract. H2RAs were the first drugs to
effectively inhibit acid secretion in these patients. However, there are several disadvan-
tages with H2RA treatment of Zollinger-Ellison syndrome: The dose requirements are
extremely high in some patients, several of them needing additional anticholinergics;
H2RAs need to be administered every four to sixhours, and the dose needs to beincreased
every year in most gastrinomapatients. These disadvantages were overcome by the use of
PPIs. By far, the most experience has been accumulated with omeprazole. Effective inhi-
bition of acid secretion (i.e., reduction of basal acid output below 10 mEq/hr in the last
hour before the next dose ofomeprazole) is achieved within few days [71]. For each indi-
vidual patient, the appropriate initial dose must be identified by upward titration and cor-
responds well with basal and maximal acid outputs as well as with the dose of H2RAs
required before starting omeprazole [71]. Patients are usually started on 60 mg of oral
omeprazole. Ifafter 23 hr (i.e., one hr before the next dose is to be taken) inhibition is still
insufficient, the dose is increased. Doses of 120 mg omeprazole and above per day may
be necessary for initial treatment. Ifeven these doses fail to sufficiently inhibit acid secre-
tion they should be split andadministered as twoportions in themorning and at night [71].
However, once control of acid output is achieved omeprazole doses should be gradually
reduced to 20 mg daily or twice daily. This strategy is successful in 68 percent of all gas-
trinoma patients, in 75 percent of those doing well on an o.d. regimen, and in 54 percent
ofpatients requiring twice daily dosing [72]. Effective inhibition ofacid secretion in gas-
trinoma patients has also been reported for lansoprazole [73], while data with pantopra-
zole are lacking.
NOW: ADVANTAGES OF FURTHER DEVELOPMENTS IN PPIS
Since the late 1980s omeprazole, the first PPI to be clinically used, became the new
gold standard for the treatment of acid-related diseases. What advantages should further
developments in substituted benzimidazoles therefore have to offer? Since the efficacy of
omeprazole with respect to inhibition of acid secretion and healing rates can hardly be
overcome, efficacy is unlikely to be an advantage rendering new PPIs even more attrac-
tive than omeprazole. Rather, further developments in PPIs qualify by improved pharma-
cokinetic properties as well as by selectivity and specificity.
Pharmacokinetics
The absorption of omeprazole and lansoprazole from enteric-coated granule formu-
lations is variable [74, 75]. Moreover, lansoprazole absorption is decreased by concomi-
tant oral food intake [75, 76]. In contrast, pantoprazole, when directly compared with
omeprazole, producedclearly smaller variations in serum concentrations after oral admin-
istration in the form of enteric-coated tablet [77, 78]. Moreover, unlike omeprazole,
absorption ofpantoprazole did not change after seven consecutive days ofadministration
[77]. This holds also for the 30 and 60 mg doses, but not for the 10 and 20 mg doses of
lansoprazole [79]. Thus, pantoprazole is characterized by constant pharmacokinetic para-
meters upon repeated once-daily dosing over one week [80]. These properties of panto-
prazole and lansoprazole (at the 30 mg dose, not at other doses) are the basis for a con-
stantly high bioavailability [80, 79] while omeprazole is characterized by a lower initial
bioavailability increasing over the first week of treatment [81, 82].
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Pantoprazole revealed clear-cut dose-linearity after oral, as well as intravenous,
administration, as determined from serum concentrations and primary pharmacokinetic
parameters (area under curve, maximal plasma concentration) [83]. On the other hand,
lansoprazole and omeprazole revealed non-linear pharmacokinetics as evidenced by a
more than proportional increase in the area under curve and maximal plasma concentra-
tions upon increasing doses [79, 84-86]. The non-linear pharmacokinetics ofomeprazole
and lansoprazole, however, apparently does not cause any clinically relevant problems.
ImprovedpH-stability
Allcurrently available PPIs are substituted benzimidazoles and weakbases, which, as
parent compounds, freely enter and leave cells unless they are protonated in acidic cell
compartments. Protonation results in trapping and concentration of the charged com-
pound, followedby activation ofthedrug, whichis nowcapable ofinhibiting the acid-pro-
ducing parietal cell enzyme, H+K+-ATPase. Ideally, protonation of PPIs should occur
selectively at very low pH levels reached only in parietal cells, while atpH levels above 2
no protonation should occur. This would make sure that PPIs are activated only in parietal
cells where they are expected to be effective, while in all other tissues, activation of PPIs
would be prevented.
Although to date no PPI fulfills these ideal criteria, pantoprazole is closer than other
PPIs. This drug exhibits the slowest protonation, i.e., activation, atslightly acidic levels of
pH above 2, especially at pH levels up to 5.0, [87], which may be reached temporarily in
tissues others than parietal cells. In accordance with these data, in vitro activation ofpan-
toprazole at pH above 3 levels off significantly faster than activation of omeprazole and
lansoprazole [88]. As a consequence, atpH 5.0activation ofpantoprazole is down to about
25 percent while 55 percent of omeprazole and lansoprazole are still activated [88].
Likewise, the potency ofpantoprazole to inhibit acid production in isolated gastric glands
increases markedly with the internal acidification ofthe glands in response to increasing-
ly effective stimuli, a pattern not observed with omeprazole and lansoprazole [89]. The
higher selectivity ofpantoprazole for the parietal cells may reduce the potential of unde-
sired activation and side effects in othertissues, although until now no such side effects of
omeprazole or lansoprazole have been identified unequivocally.
On the other hand, at the highly acidic pH levels reached in parietal cells, pantopra-
zole is activated at the same rate as are omeprazole and lansoprazole. Thus, the acid-
inhibitory capacity ofpantoprazole in parietal cells is not compromised by the diminished
protonation at higher pH levels.
Selective binding to the proton pump
Binding of radioactively labeled PPIs to trypsin-generated fragments of the H+K+-
ATPase identified the cysteine residues within the enzyme molecule to which the drugs
bind covalently, thereby irreversibly inhibiting the enzyme's activity. While the Cys813
residue in themembrane-spanning segmentM5/M6 is the target ofall three available PPIs,
omeprazole (Cys892 inM7/M8) andlansoprazole (Cys892 inM7/M8 andCys321 in M3/M4)
bind to additional targets [90, 91]. Thus, binding toCys813 in M5/M6 apparently is crucial
for inhibiting the H+K+-ATPase.
To date, pantoprazole is the only PPI selectively binding to this cysteine residue.
Additional binding ofomeprazole and lansoprazole to Cys892 andCys321 does not appear
to be related to the specific acid-inhibitory effect of these substituted benzimidazoles.
Undesired effects secondary to binding ofomeprazole and lansoprazole to these addition-
al cysteine residues have not been identified.
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Interaction with the cytochrome P450 enzyme system
Pantoprazole has a significantly lowerpotential than omeprazole and lansoprazole to
interact with the cytochrome P450 system [92]. This issue is discussed in a separate con-
tribution to this symposium.
Advantages offurtherdevelopments in PPIs: summary
Compared to omeprazole and lansoprazole, pantoprazole is characterized by
improved pharmacokinetics and pH-stability, selective binding to the crucial cysteine
residue within the H+K+-ATPase molecule, and a very low potential to interact with the
cytochrome P450 enzyme system. Although it may be desirable to use a drug with these
characteristics, it must be kept in mind that the safety standard ofomeprazole and lanso-
prazole is also veryhigh. No serious side effects have become apparent everduring almost
one decade ofclinical use ofomeprazole in numerous patients.
NOW: RATIONALES FOR THE USE OF PPIS IN
ERADICATION OF H. PYLORI
The horizon ofindications for the PPIs is extensively widening since it became clear
that these drugs can be successfully used not only in the conventional acid-inhibitory
treatment ofrefluxesophagitis and gastroduodenal ulcers, but also in the eradication ofH.
pylori. The traditional concept ofgastro-duodenal ulcer disease as a "peptic" disorder has
been revolutionized by the recognition ofH. pylori as an essential etiological factor. The
dictum "No acid - no ulcer" had to be expanded to "No acid and no H. pylori - no
ulcer." Monotherapy with acid-inhibiting drugs heals ulcers, but fails to eradicate H.
pylori. Thus, this prerequisite for subsequent ulcer relapses persists in the gastric mucosa,
unless it is eradicated by other treatments. These are neither monotherapies nor combina-
tions of antibiotics as such regimens are successful in only a minority of patients.
However, addition of acid-inhibiting drugs, especially PPIs, dramatically increases the
eradication success of antibiotic regimens, especially those containing clarithromycin,
amoxicillin and/or metronidazole [93, 94]. But how might PPI-treatment eliminate the
conditions for colonization of the gastric mucosa by H. pylori?
Several hypotheses have been proposed: In vitro, all PPIs exhibit antimicrobial activ-
ity against H. pylori. However, in vivo PPIs fail to eradicate the bacterium; moreover, H.
pylori does not provide an acidic compartment in which PPIs could be protonated and
activated. Thus, the direct antimicrobial effect ofPPIs does not appear to contribute to the
favorable effect of these drugs in vivo. On the other hand, PPIs may cause a loss of the
acidic microenvironment at the epithelial surface where H. pyloriis found directly under
the mucus layer. Moreover, antibodies directed against H. pylorimay be protected against
acid/pepsin-induced degradation when the intragastric pH is elevated due to PPI treat-
ment. Finally, such treatment may provide optimal conditions for neutrophil function in
the gastric mucus bicarbonate layer. None of these hypotheses have been unequivocally
proven ordisproven. Thus, interestis focusing on potentiating interactions between antibi-
otics and acid-inhibitory therapy.
Increasedgastric mucosal concentration ofantibiotics?
It is tempting to speculate that PPI-induced elevation of gastric pH may increase the
mucosal concentration of antibiotics. However, in the mucosa of the corpus and antrum
omeprazole (20 to 80mg/day) failed to increase the concentration ofamoxicillin [95, 96],
an antibiotic widely used for H. pylorieradication.
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Increased bioavailability ofantibiotics?
Another possibility would be that PPIs and antibiotics would mutually increase their
bioavailability. Again, this hypothesis was disproven. The bioavailability of amoxicillin
under placebo conditions was not increased by addition ofomeprazole 20 mg nor was the
bioavailability of omeprazole increased by addition of amoxicillin, clarithromycin or
metronidazole [95, 96]. Likewise, increasing the omeprazole dose to 40 and 80 mg had no
effect on the bioavailability of amoxicillin.
Increased gastric release ofantibiotics?
To be active against H. pylori, antibiotics should be present at high concentrations
between the gastric epithelial surface and the mucus layer. The effect of amoxicillin
against H. pylori is considered mainly a systemic effect not locally provided by luminal-
ly acting drugs. Since H. pylori is rarely found within the gastric epithelium but rather on
the epithelial surface directly under the mucus layer, amoxicillin would reach the highest
concentration at the bacteria themselves if the gastric mucosa would actively secrete the
systemically circulating drug. In fact, after i.v. injection amoxicillin is secreted into the
gastric juice, the secretion being threefold increased after administration of omeprazole
(40 mg twice daily.) [97]. Thus, the PPI might potentiate the amoxicillin effect against H.
pylori by increasing gastric mucosal release of the antibiotic.
Adjustment ofgastric pH to levels appropriatefor optimal activity ofantibiotics?
In vitro, the activity of several antibiotics against H. pylori is increased when the pH
is elevated from 5.5 to 7.5 [98, 99]. Antibiotics profit from pH elevation to differing
extents. The activities of amoxicillin and some macrolides are increased by one to two
orders ofmagnitude [98, 99] offering a possible explanation oftheir increased efficacy in
the presence of PPIs in vivo. However, the actual pH of the microenvironment where the
bacterium colonizes the gastric epithelial surface is not known. Thus, definite proof is
lacking that PPIs potentiate the effect ofantibiotics by adjusting the pH appropriately for
optimal activity of the antibiotic, and the relevance of pH-dependent inhibitory antimi-
crobial drug concentrations in vitro remains to be determined.
SUMMARY
PPIs have been established as the new "gold standard" for traditional acid-inhibitory
treatment ofthe so called "peptic" diseases. Due to the high antisecretory and ulcer-heal-
ing potency of omeprazole, no major improvements of the efficacy in ulcer healing and
pain relief can be expected. Pantoprazole, as a further development in PPIs, is character-
ized by improved pharmacokinetic behavior as well as by higher tissue selectivity and
binding specificity and by a very low potential to interact with the cytochrome P450
enzyme system. These characteristics may provide the basis for low potential for side
effects and for more favorable interaction profile, although the clinical relevance ofthese
potential advantages remains to be proven. Reflux esophagitis will remain a domain for
the traditional use ofPPIs also in the future. However, in the treatment ofgastroduodenal
ulcers the acid inhibitory potential ofPPIs will be used mainly to facilitate the eradication
ofH. pylori.
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